ThinkstockThe field of pharmaceuticals is very well established and often is considered to be a very defensive sector. As such, investors flock to the drug sector in times of uncertainty. But what…
ThinkstockTuesday saw the wrap up of the 2013 European Society of Medical Oncology (ESMO) conference in Amsterdam, which featured key data from several of the companies covered by the biotech analysts at…
ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive on large cap biotechnology names. Acknowledging in their recent report that the…
Any time you see a merger announcement, you see a myriad of press releases pertaining to law firms and lawyers investigating the terms of the deal. This is in one sense the…
Jon C. Ogg Jon OggThis will be an interesting week for Wall Street analyst coverage as many traders, investors and analysts are out ahead of Labor Day. Still, we are seeing a surprising number of…
ThinkstockAmgen Inc. (NASDAQ: AMGN) wants to regain its status as the largest publicly traded biotech in the U.S. The company formalized a buyout of cancer drug maker Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) for about…
Jon C. Ogg ThinkstockWith the Federal Reserve reminding investors yesterday that it can raise or lower asset purchases in its quantitative easing program based on the data, all eyes shift to tomorrow’s employment numbers. With…
July 31, 2013: U.S. equity markets opened higher this morning as traders and investors this afternoon’s announcement from the FOMC. In Europe, the unemployment rate in the eurozone was unchanged at 12.1%,…
July 30, 2013: U.S. equity markets opened higher this morning as traders and investors wait for tomorrow’s announcement from the FOMC. There was little economic data published today. In the U.S., the…
courtesy of FordThe equity analysts and strategists at UBS A.G. (NYSE: UBS) expect to see U.S. equities continue to conform largely to the “1994 Playbook” in which stocks meander higher after correcting…
ThinkstockOn Friday after the market closed, biotech giant Amgen Inc. (NASDAQ: AMGN) made an unsolicited $120 per share bid for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) that was rejected. The company has now…
ThinkstockAlthough Amgen Inc.’s (NASDAQ: AMGN) $10 billion offer for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) was unsolicited and not exactly a stalking horse bid, that’s what many observers expect to be the result.…
July 1, 2013: U.S. equity markets opened higher this morning after a blast of economic data from both Asia and Europe. In China, June manufacturing PMI slid lower. Japan’s economics minister said…
ThinkstockCancer-drug developer Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) issued a terse press release yesterday, saying it had “received and rejected” a buyout offer from Amgen Inc. (NASDAQ: AMGN) for $120 per share. Shares…
Paul Ausick ThinkstockBiotech has strongly outperformed the S&P 500 since January of 2011. The NASDAQ Biotechnology Index (NBI) is up 90%, and the AMEX Biotechnology index (BTK) is up 50%, versus the 28% gain…
